Cargando…

Biomarkers in long COVID-19: A systematic review

PURPOSE: Long COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yun-Ju, Liu, Shou-Hou, Manachevakul, Sumatchara, Lee, Te-An, Kuo, Chun-Tse, Bello, Dhimiter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895110/
https://www.ncbi.nlm.nih.gov/pubmed/36744129
http://dx.doi.org/10.3389/fmed.2023.1085988
_version_ 1784881880575770624
author Lai, Yun-Ju
Liu, Shou-Hou
Manachevakul, Sumatchara
Lee, Te-An
Kuo, Chun-Tse
Bello, Dhimiter
author_facet Lai, Yun-Ju
Liu, Shou-Hou
Manachevakul, Sumatchara
Lee, Te-An
Kuo, Chun-Tse
Bello, Dhimiter
author_sort Lai, Yun-Ju
collection PubMed
description PURPOSE: Long COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers associated with long COVID symptoms and their roles in disease progression remain undetermined. This study aims to systematically evaluate blood biomarkers that may act as indicators or therapeutic targets for long COVID. METHODS: A systematic literature review in PubMed, Embase, and CINAHL was performed on 18 August 2022. The search keywords long COVID-19 symptoms and biomarkers were used to filter out the eligible studies, which were then carefully evaluated. RESULTS: Identified from 28 studies and representing six biological classifications, 113 biomarkers were significantly associated with long COVID: (1) Cytokine/Chemokine (38, 33.6%); (2) Biochemical markers (24, 21.2%); (3) Vascular markers (20, 17.7%); (4) Neurological markers (6, 5.3%); (5) Acute phase protein (5, 4.4%); and (6) Others (20, 17.7%). Compared with healthy control or recovered patients without long COVID symptoms, 79 biomarkers were increased, 29 were decreased, and 5 required further determination in the long COVID patients. Of these, up-regulated Interleukin 6, C-reactive protein, and tumor necrosis factor alpha might serve as the potential diagnostic biomarkers for long COVID. Moreover, long COVID patients with neurological symptoms exhibited higher levels of neurofilament light chain and glial fibrillary acidic protein whereas those with pulmonary symptoms exhibited a higher level of transforming growth factor beta. CONCLUSION: Long COVID patients present elevated inflammatory biomarkers after initial infection. Our study found significant associations between specific biomarkers and long COVID symptoms. Further investigations are warranted to identify a core set of blood biomarkers that can be used to diagnose and manage long COVID patients in clinical practice.
format Online
Article
Text
id pubmed-9895110
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98951102023-02-04 Biomarkers in long COVID-19: A systematic review Lai, Yun-Ju Liu, Shou-Hou Manachevakul, Sumatchara Lee, Te-An Kuo, Chun-Tse Bello, Dhimiter Front Med (Lausanne) Medicine PURPOSE: Long COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers associated with long COVID symptoms and their roles in disease progression remain undetermined. This study aims to systematically evaluate blood biomarkers that may act as indicators or therapeutic targets for long COVID. METHODS: A systematic literature review in PubMed, Embase, and CINAHL was performed on 18 August 2022. The search keywords long COVID-19 symptoms and biomarkers were used to filter out the eligible studies, which were then carefully evaluated. RESULTS: Identified from 28 studies and representing six biological classifications, 113 biomarkers were significantly associated with long COVID: (1) Cytokine/Chemokine (38, 33.6%); (2) Biochemical markers (24, 21.2%); (3) Vascular markers (20, 17.7%); (4) Neurological markers (6, 5.3%); (5) Acute phase protein (5, 4.4%); and (6) Others (20, 17.7%). Compared with healthy control or recovered patients without long COVID symptoms, 79 biomarkers were increased, 29 were decreased, and 5 required further determination in the long COVID patients. Of these, up-regulated Interleukin 6, C-reactive protein, and tumor necrosis factor alpha might serve as the potential diagnostic biomarkers for long COVID. Moreover, long COVID patients with neurological symptoms exhibited higher levels of neurofilament light chain and glial fibrillary acidic protein whereas those with pulmonary symptoms exhibited a higher level of transforming growth factor beta. CONCLUSION: Long COVID patients present elevated inflammatory biomarkers after initial infection. Our study found significant associations between specific biomarkers and long COVID symptoms. Further investigations are warranted to identify a core set of blood biomarkers that can be used to diagnose and manage long COVID patients in clinical practice. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9895110/ /pubmed/36744129 http://dx.doi.org/10.3389/fmed.2023.1085988 Text en Copyright © 2023 Lai, Liu, Manachevakul, Lee, Kuo and Bello. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Lai, Yun-Ju
Liu, Shou-Hou
Manachevakul, Sumatchara
Lee, Te-An
Kuo, Chun-Tse
Bello, Dhimiter
Biomarkers in long COVID-19: A systematic review
title Biomarkers in long COVID-19: A systematic review
title_full Biomarkers in long COVID-19: A systematic review
title_fullStr Biomarkers in long COVID-19: A systematic review
title_full_unstemmed Biomarkers in long COVID-19: A systematic review
title_short Biomarkers in long COVID-19: A systematic review
title_sort biomarkers in long covid-19: a systematic review
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895110/
https://www.ncbi.nlm.nih.gov/pubmed/36744129
http://dx.doi.org/10.3389/fmed.2023.1085988
work_keys_str_mv AT laiyunju biomarkersinlongcovid19asystematicreview
AT liushouhou biomarkersinlongcovid19asystematicreview
AT manachevakulsumatchara biomarkersinlongcovid19asystematicreview
AT leetean biomarkersinlongcovid19asystematicreview
AT kuochuntse biomarkersinlongcovid19asystematicreview
AT bellodhimiter biomarkersinlongcovid19asystematicreview